Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bosutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 19/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 5/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 4/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 1/20 | 1.00 |
| ▸ | HCK known ✓ | P08631 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | WEE2 | P0C1S8 | 2/20 | 1.00 |
| ▸ | WEE1 | P30291 | 2/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bosutinib SCHEMBL158390 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL19207253 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29389315 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL2887945 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29350234 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL19207270 | 0.98 | SRC (0.97) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL19207277 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL30453343 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL676669 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL30453317 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023025302-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | 清华大学 | 2023-03-02 | — | — | WO | claimed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-3797770-B1 | SOFTGEL CAPSULE COMPRISING APALUTAMIDE | ARAGON PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | TWELVE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4585268-A2 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | Twelve Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-3350183-B1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2025-04-02 | — | — | EP | disclosed |
| WO-2024238387-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-11-21 | — | — | WO | disclosed |
| CN-114656464-B | 6,7,8, 9-Tetrahydro-3H-pyrazolo [4,3-f ] isoquinoline derivatives useful in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-112313213-B | 3-amino pyrazole compound and application thereof | 上海海和药物研究开发股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| CN-112351971-B | Quinoline or quinazoline compound and application thereof | 上海海和药物研究开发股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3778585-B1 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2022-10-19 | — | — | EP | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3474856-B1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20220241287-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220135576-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| CN-114230571-A | Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof | 无限药品股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3119397-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | INFINITY PHARMACEUTICALS INC (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241287-A1 | COMBINATION THERAPIES | FLT3, TLR3, BTK | SRC 67/4885ABL1 65/4885BCR 118/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | SRC 40/4885ABL1 897/4885BCR 2826/4885 |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | SRC 109/4885ABL1 198/4885BCR 944/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | SRC 241/4885ABL1 353/4885BCR 1101/4885 |
| US-20220135576-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PIK3CA, PIK3C2A, PIK3CD | SRC 109/4885ABL1 198/4885BCR 944/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | SRC 817/4885ABL1 1101/4885BCR 743/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | SRC 331/4885ABL1 1083/4885BCR 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.